Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Maria Nuria Peralta-MorenoDepartment of Materials Science and Physical Chemistry, University of Barcelona, and the Institut de Recerca en Quimica Teorica i Computacional (IQTCUB), 08028 Barcelona, Spain.ORCID 0000-0002-7762-0406
Vanessa Anton-MuñozFacultad de Farmacia y Bioquímica, Universidad Nacional Mayor de San Marcos, Jr. Puno 1002, Lima 15001, Peru.ORCID 0009-0000-1640-6177
David Ortega-AlarconInstitute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain.ORCID 0000-0003-1885-4365
Ana Jimenez-AlesancoInstitute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain.
Sonia VegaInstitute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain.
Olga AbianInstitute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain.ORCID 0000-0001-5664-1729
Adrian Velazquez-CampoyInstitute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain.ORCID 0000-0001-5702-4538
Timothy M ThomsonCentro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas Digestivas (CIBERehd), 28029 Madrid, Spain.ORCID 0000-0002-4670-9440
José Manuel Granadino-RoldánDepartamento de Química Física y Analítica, Facultad de Ciencias Experimentales, Universidad de Jaén, Campus "Las Lagunillas" s/n, 23071 Jaén, Spain.
Claudia MachicadoInstitute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain.ORCID 0000-0001-6140-2423
Jaime Rubio-MartinezDepartment of Materials Science and Physical Chemistry, University of Barcelona, and the Institut de Recerca en Quimica Teorica i Computacional (IQTCUB), 08028 Barcelona, Spain.ORCID 0000-0002-5529-2325
Funding
Agency for Administration of University and Research 2020PANDE00048Agency for Administration of University and Research 2021SGR00350Diputación General de Aragón (Digestive Pathology Group) B25_20RDiputación General de Aragón (predoctoral contract 2019)Diputación General de Aragón (Protein Targets and Bioactive Compounds Group) E45_20RERDF A way of Making Europe PID2021-127296OB-I00Fondo de Investigaciones Sanitarias from Instituto de Salud Carlos III and European Union (ERDF/ESF, "Investing in your future") PI18/00349Fondo de Investigaciones Sanitarias from Instituto de Salud Carlos III and European Union (ERDF/ESF, "Investing in your future") PI21/00394Fondo Investiga Covid-19 from Instituto de Investigación Sanitaria de Aragón IIS-AFundación hnaMinistry of Science and Innovation MCIN/AEI/10.13039/501100011033/Plan Nacional de I + D PID-107139RB-C21Plataforma Temática Interdisciplinar Salud Global PTI-SG+ SGL2103019Spanish Ministry of Economy and Competitiveness BES-2017-080739Spanish Ministry of Economy and Competitiveness BFU2016-78232-PSpanish National Research Council COV-006Spanish National Research Council COV-201Spanish Structures and Excellence María de Maeztu program CEX2021-001202-MUniversitat de Barcelona PREDOCS-UB 2020 grant 5760700
6 · The paper itself
Abstract
Over 750 million cases of COVID-19, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), have been reported since the onset of the global outbreak. The need for effective treatments has spurred intensive research for therapeutic agents based on pharmaceutical repositioning or natural products. In light of prior studies asserting the bioactivity of natural compounds of the autochthonous Peruvian flora, the present study focuses on the identification SARS-CoV-2 M
Indexed as
allosteric inhibitiondockingdrug designHyperosideMM-PB/GBSA approachmolecular dynamicsPeruvian natural plantsSARS-CoV-2 main protease
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Autochthonous Peruvian Natural Plants as Potential SARS-CoV-2 M · full record | OpenQuestion